Shentu Yue

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Y. Shentu, A. Tafreshi, M. O'Brien, 2016, The New England journal of medicine.

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Y. Shentu, R. Herbst, M. Ahn, 2016, The Lancet.

Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes

Yue Shentu, Maria Alba, Edmund Luo, 2011, Diabetes Care.

Principal stratum strategy: Potential role in drug development

K. Rufibach, Y. Shentu, D. Mehrotra, 2020, Pharmaceutical statistics.

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

Y. Shentu, R. Herbst, M. Ahn, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.

Y. Shentu, B. Goldstein, V. Fonseca, 2013, Journal of diabetes and its complications.

Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024.

Y. Shentu, A. Tafreshi, M. O'Brien, 2017 .

KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%

Y. Shentu, A. Tafreshi, M. O'Brien, 2016 .

A note on dichotomization of continuous response variable in the presence of contamination and model misspecification

Minge Xie, Yue Shentu, Min‐ge Xie, 2010, Statistics in medicine.